Stereotactic body radiation therapy for intermediate-risk prostate cancer with VMAT and real-time electromagnetic tracking: A phase 2 study

By D’Agostino GR, Mancosu P, Di Brina L, et al
Published September 1, 2020

Key Takeaways

In this phase 2 study, patients affected by histologically proven prostate adenocarcinoma and National Comprehensive Cancer Network (NCCN) intermediate class of risk were administered stereotactic body radiation treatment delivered by volumetric modulated arc therapy with flattening filter free beams; the treatment was gated employing real-time electromagnetic transponder system to maximize precision of radiotherapy and, potentially, to decrease toxicities. Enrollment of 36 patients was done. They observed a genitourinary acute toxicity in 21 patients (dysuria grade [G] 1: 41.7%, G2: 16.7%) and gastrointestinal acute toxicity in 9 patients (proctitis G1: 19.4%, G2: 5.6%). Three-year biochemical recurrence-free survival of 89.8% was observed (International Society of Urologic Pathology Grade Group 2: 100%, Grade Group 3: 77.1%). Outcomes suggest that for managing intermediate-risk prostate cancer, ultrahypofractionated radiotherapy, delivered with flattening filter free-volumetric modulated arc therapy and gated by electromagnetic transponders, is a valid option.

Read the full article on American Journal of Clinical Oncology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter